anti-HER2 X anti-CD3 (Emergent Biosolutions)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-HER2 X anti-CD3 (Emergent Biosolutions)
Drug Alias NameT-Scorp (Emergent Biosolutions)
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionT cell surface glycoprotein CD3 stimulantsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEmergent Biosolutions Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmergent Biosolutions Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A